Epidemiology of invasive candidiasis
The DOI matches its Crossref record; 211 of the 212 references it cites were found in a registry or an index.
Abstract
Purpose of review This review covers candidaemia in numbers, susceptibility issues, host groups, risk factors and outcome. Recent findings The incidence of candidaemia has increased over the last decades. Candida glabrata is particularly common in the northern hemisphere and with increasing age whilst the opposite is true for C. parapsilosis, C. glabrata, C. krusei and a number of emerging species are not fully susceptible to azoles. C. parapsilosis and C. guilliermondii are not fully susceptible to echinocandins. Increasing rates of C. parapsilosis have been observed at centres with a high use of echinocandins, and outcome for this species is not superior comparing echinocandins with fluconazole. Acquired azole resistance has recently been described in as many as a third of 19% resistant isolates and echinocandin resistance has emerged and been detected as early as day 12 of echinocandin therapy. ICU stay and abdominal surgery are among the most important risk factors. Outcome is dependent on species involved, timing, dosing and choice of therapy and management of the primary focus of infection. However, host factors are dominating predictors of mortality in recent studies of ICU candidiasis. Summary The changing epidemiology highlights the need for close monitoring of local incidence, species distribution and susceptibility in order to optimize therapy and outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparisons of the incidence across countries is difficult as recent local epidemiological data was only available for 20 of the countries and the others used an incidence of 5 per 100,000 cases for their estimations [46].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [46]
In the citing paper
“Specifically, C. glabrata has become an important pathogen in North America, Europe (with the exception of Spain), and Australia, whereas C. parapsilosis is the dominant non-albicans species in South America, Japan, and Spain [8,9,10].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [9]
Citations
Cites
Items 201–211 of 211
Sugita, T., Takeo, K., Ohkusu, M., Virtudazo, E. V., Takashima, M., Asako, E., Ohshima, F., Harada, S., Yanaka, C., Nishikawa, A., et al. (2004) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2004.tb03602.x · Cited by 33
Candida spp. bloodstream infection: influence of antifungal treatment on outcome
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., Pitart, C., & Mensa, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp495 · Cited by 33
O’Day, D. M., Ray, W. A., Robinson, R. D., & Head, W. S. (1987) · PubMed · Cited by 31
Sterling, T. R., Gasser, R. A., & Ziegler, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.1.187 · Cited by 28
A nosocomial outbreak of Candida parapsilosis in southern Sweden verified by genotyping
Brillowska‐Dąbrowska, A., Schön, T., Pannanusorn, S., Lönnbro, N., Bernhoff, L., Bonnedal, J., Häggström, J., Wistedt, A. C., Fernandez, V., & Arendrup, M. C. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540802585301 · Cited by 27
Self-citationEditorial Response: The Epidemiology of Invasive Mycoses--Narrowing the Gap
Pfaller, M. A. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1148 · Cited by 26
The epidemiology of fungal infections
Lockhart, S. R., Diekema, D. J., & Pfaller, M. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00001-3 · Cited by 25
Lee, I., Zaoutis, T. E., Fishman, N. O., Morales, K. H., Nachamkin, I., & Lautenbach, E. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.12.011 · Cited by 21
Caspofungin: a new therapeutic option for fungal endocarditis
Nevado, J., de Alarcón, A., & Hernández, A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01078.x · Cited by 17
Antifungal prophylaxis in the intensive care unit: Who should get it?*
Rex, J. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208110.36504.19 · Cited by 15
Economic aspects of treatment for fungal infections in cancer patients
Torfs, K. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01575127 · Cited by 14
Research works printed but not linked: 3
- Hsin-Yun, 2010, Int J Antimicrob Agents, 353, 211
- Pfaller, 2007, J Invasive Fungal Infect, 1, 74
- Oxman, 2010, hemother, 65, 1460
Cited by
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
“Comparisons of the incidence across countries is difficult as recent local epidemiological data was only available for 20 of the countries and the others used an incidence of 5 per 100,000 cases for their estimations [46].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Self-citationBranzk, N., Lubojemska, A., Hardison, S. E., Wang, Q., Gutierrez, M. G., Brown, G. D., & Papayannopoulos, V. (2014) · Nature Immunology · doi:10.1038/ni.2987 · Cited by 1,037
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Antifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Metadata
- Authors
- Arendrup, M. C.
- Affiliations
- Statens Serum Institut (DK)
- Corresponding author
- Arendrup, Maiken C
- ORCID
- Arendrup, Maiken C
- Venue
- Current Opinion in Critical Care
- Published
- 2010-10
- Volume
- 16
- Issue
- 5
- Pages
- 445-452
- ISSN
- 1070-5295 (ISSN-L)
- OpenAlex
- W2088977070
- Cited by
- 376
- References
- 212
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 12 · 2023: 15 · 2022: 14 · 2021: 24 · 2020: 30 · 2019: 25 · 2018: 35 · 2017: 27 · 2016: 24 · 2015: 33 · 2014: 27 · 2013: 35 · 2012: 32
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Critical Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- invasive candidiasis, candidemia, Candida parapsilosis, Candida glabrata, Candida krusei, Candida guilliermondii, antifungal susceptibility, azole resistance, echinocandin resistance, fluconazole, risk factors, mortality, intensive care unit, abdominal surgery, antifungal therapy
- MeSH terms
- Disease Susceptibility, Humans, Intensive Care Units, Species Specificity, Candidiasis, Invasive, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.